Breast Cancer Clinical Trial
Official title:
Optical Biosensor for the Early Detection of Breast Cancer
RATIONALE: Diagnostic procedures that measure biomarker levels in nipple section and blood
samples, may help in the early detection of breast cancer.
PURPOSE: This clinical trial is studying nipple secretion samples in detecting breast cancer
in patients and healthy participants undergoing breast cancer screening, breast diagnostic
studies, or treatment for benign breast disease.
OBJECTIVES:
- To determine CEA levels in nipple secretions and blood samples from breast cancer
patients and normal controls.
- To determine the sensitivity and specificity of measuring CEA levels in nipple
secretions and blood samples for the detection of breast cancer.
- To validate the optical biosensor CEA levels measured in blood and nipple secretions in
breast cancer patients and normal controls compared with standard protein assays.
- To develop a profile of proteins present in affected vs unaffected breasts using mass
spectrometry.
OUTLINE: Patients and participants undergo nipple secretion and blood sample collection at
baseline and at 1 month for evaluation of levels of carcinoembryonic antigen (CEA) and
patterns of protein expression that may indicate the presence of early-stage breast cancer.
Nipple secretions are obtained from both the affected and unaffected breasts via capillary,
aspiration (nipple aspirate fluid [NAF]), and nipple blot . CEA levels are measured in serum
samples, NAF, and other nipple secretions using standard CEA protein assays. Nipple
secretions obtained by nipple blot are analyzed by nipple blot assay to determine the
feasibility of using this technique. The results of the nipple blot assay are then compared
with the results of standard protein assays to evaluate the sensitivity and specificity of
the nipple blot test. CEA expression is also determined in breast tissue specimens obtained
from patients undergoing diagnostic biopsy. Specimens are examined by IHC for tissue CEA
levels. Proteomic profiles in NAF and serum samples are measured using liquid chromatography
mass spectrometry and then compared with proteomic profiles in normal healthy controls.
Once the feasibility of the nipple blot assay has been determined, an optical biosensor will
be developed to detect fluorescent-labeled antibodies directed against CEA found in serum and
breast sections. Optical biosensor CEA levels measured in breast cancer patients and normal
controls will then be compared to standard protein assays for evaluation of the sensitivity
and specificity of biosensor measurements.
After completion of study intervention, patients and participants are followed for 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |